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ABSTRACT The lungs of individuals with cystic ﬁbrosis (CF) become chronically in-
fected with Pseudomonas aeruginosa that is difﬁcult to eradicate by antibiotic treat-
ment. Two key P. aeruginosa antibiotic resistance mechanisms are the AmpC
-lactamase that degrades -lactam antibiotics and MexXYOprM, a three-protein ef-
ﬂux pump that expels aminoglycoside antibiotics from the bacterial cells. Levels of
antibiotic resistance gene expression are likely to be a key factor in antibiotic resis-
tance but have not been determined during infection. The aims of this research
were to investigate the expression of the ampC and mexX genes during infection in
patients with CF and in bacteria isolated from the same patients and grown under
laboratory conditions. P. aeruginosa isolates from 36 CF patients were grown in labo-
ratory culture and gene expression measured by reverse transcription-quantitative
PCR (RT-qPCR). The expression of ampC varied over 20,000-fold and that of mexX
over 2,000-fold between isolates. The median expression levels of both genes were
increased by the presence of subinhibitory concentrations of antibiotics. To measure
P. aeruginosa gene expression during infection, we carried out RT-qPCR using RNA
extracted from fresh sputum samples obtained from 31 patients. The expression of
ampC varied over 4,000-fold, while mexX expression varied over 100-fold, between
patients. Despite these wide variations, median levels of expression of ampC in bac-
teria in sputum were similar to those in laboratory-grown bacteria. The expression of
mexX was higher in sputum than in laboratory-grown bacteria. Overall, our data
demonstrate that genes that contribute to antibiotic resistance can be highly ex-
pressed in patients, but there is extensive isolate-to-isolate and patient-to-patient
variation.
KEYWORDS Pseudomonas aeruginosa, antibiotic resistance, cystic ﬁbrosis, gene
expression, beta-lactamase, efﬂux pump, efﬂux pumps
Pseudomonas aeruginosa infects the lungs of individuals with cystic ﬁbrosis (CF), withinfections lasting for years or decades (1–3). Chronic P. aeruginosa infections in
patients with CF are associated with progressive clinical decline and increased mor-
bidity, leading to respiratory failure and premature death (4–6). Aggressive antibiotic
treatment can eliminate P. aeruginosa from the lower airways during the initial stage of
infection (1, 3). However, once chronic infection becomes established, existing antibi-
otic treatment regimens usually fail to eradicate infection, although they reduce the
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bacterial burden (7, 8). Treatment differs between patients and between CF care centers
but typically involves the use of one or more aminoglycosides, such as tobramycin; a
carbapenem, including meropenem; a ﬂuoroquinolone, such as ciproﬂoxacin; and in
some cases, colistin, a polymyxin (9, 10). P. aeruginosa undergoes genetic changes
during the course of chronic infection that help it adapt to the CF airway microenvi-
ronment, including mutations associated with increased antibiotic resistance (11, 12).
CF is characterized by periods of clinical stability interspersed with pulmonary exacer-
bations that are associated with reduced pulmonary lung function and require hospi-
talization, though the relationship between bacterial infection and exacerbation is
unclear (1).
P. aeruginosa has multiple antibiotic resistance mechanisms (13–15). The expression
of a number of these is induced by substrate antibiotics leading to increased resistance
in a process known as adaptive resistance (13, 16–18). Two key antibiotic-inducible
systems are AmpC -lactamase, which confers resistance to members of the -lactam
class of antibiotics (14), and an efﬂux pump, MexXYOprM, that is associated with
resistance to aminoglycosides and ﬂuoroquinolones, among other antibiotics (19, 20).
-Lactam antibiotics increase expression of the ampC gene, and aminoglycoside sub-
strates increase expression of the mexXY genes, which are expressed as an operon (21).
P. aeruginosa isolates cultured from individuals with CF commonly possess genetic
mutations that give rise to increased ampC and mexXY expression and are associated
with increased -lactam and aminoglycoside antibiotic resistance (22–31).
The physiology of P. aeruginosa growing in pure culture in laboratory medium is
likely to be quite different from that in the CF airway where they exist in bioﬁlms within
the context of the infected host, with multiple other microbial species present (32, 33).
These physiological differences may have profound effects on bacterial gene expres-
sion and antibiotic resistance (34, 35). However, there is limited information on the
expression of antibiotic resistance genes as it occurs during infection. In a pioneering
study, RNA was extracted from P. aeruginosa in samples of sputum from a single patient
without any ex vivo incubation or laboratory culture of the bacteria in order to analyze
bacterial gene expression in vivo in the patient (36). The expression of multiple genes,
including ampC and the mexXY efﬂux genes, occurred at a much higher level during
infection in the patient than in bacteria isolated from the patient and grown under
laboratory conditions.
The overall aims of this study were to measure the expression of ampC and mexX
antibiotic resistance genes during infection in CF, and to determine how gene expres-
sion during infection relates to expression and antibiotic resistance of bacteria in
laboratory culture.
RESULTS
Expression of antibiotic resistance genes in P. aeruginosa in sputum from
patients with CF. Expectorated sputum was obtained from 36 patients with CF and P.
aeruginosa infection of different ages (range, 11 to 58 years; median age, 24 years)
attending four different CF centers (Dunedin, Hobart, and two independent hospitals in
Brisbane). Patient demographics are listed in Table 1. Two of the patients were
transiently infected with P. aeruginosa, with the remainder of the patients being
chronically infected.
The expression of ampC and mexX antibiotic resistance genes was measured by
extracting RNA from expectorated sputum and then carrying out RT-qPCR. Gene
expression was quantiﬁed for 31 of the 36 samples analyzed, with the remaining
samples either giving no detectable expression of the P. aeruginosa genes tested (2
samples) or showing expression at a level that was too low for quantiﬁcation
(3 samples; see Table S1 in the supplemental material). Among the quantiﬁable
samples, the expression of ampC varied over 4,000-fold (range, 0.004 to 24.6; median,
1.74; 25th to 75th percentiles, 0.34 to 3.71, relative to the reference genes), while mexX
expression varied by approximately 100-fold (range, 0066 to 6.65; median, 1.77; 25th to
75th percentiles 0.426 to 3.06) (Fig. 1A and Table S1). There was no evidence of
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correlation between the expression of ampC and the expression of mexX (P  0.559)
(Fig. 1B). Taken together, these data indicate that both ampC and mexX are expressed
during CF airway infection, but there is very marked variation in the expression of these
genes across sputum samples from different patients.
Correlations between resistances to different antibiotics. At the same time that
samples were collected for analysis of gene expression, P. aeruginosa was isolated from
sputum samples. We ﬁrst investigated whether MICs for different antibiotics were
correlated. MICs were determined for 6 antibiotics for isolates from 28 patients. The
TABLE 1 Isolates of Pseudomonas aeruginosa used in this study
Isolatea Source and/or description Patient sexb Patient age (yr) Reference or source
Patients with cystic ﬁbrosis
001C Dunedin M 51 This study
002C Dunedin M 25 This study
003B Dunedin F 36 This study
004 Dunedin M 20 This study
005A Dunedin M 28 This study
009B Dunedin M 30 This study
012-4 Dunedin F 24 This study
012-2 Dunedin F 24 This study
014-2A Dunedin M 43 This study
015A Dunedin F 28 This study
021-3A Dunedin M 23 This study
030-1 Dunedin M 58 This study
036-1 Dunedin F 31 This study
039-1 Dunedin M 22 This study
284 Tasmania F 20 This study
451 Tasmania F 23 This study
310A Tasmania F 26 This study
454A Tasmania M 24 This study
399 Tasmania F 28 This study
254 Tasmania M 50 This study
409 Tasmania F 22 This study
001-A1 Brisbane F 16 This study
002-A2 Brisbane F 11 This study
003-A1 Brisbane F 11 This study
006-A2 Brisbane F 15 This study
007-A1 Brisbane M 16 This study
008-A1 Brisbane F 12 This study
403-102 Brisbane F 22 This study
403-110 Brisbane F 22 This study
403-103 Brisbane M 38 This study
403-104 Brisbane M 28 This study
403-105 Brisbane F 19 This study
403-106 Brisbane F 36 This study
403-107 Brisbane F 26 This study
403-108 Brisbane F 23 This study
403-109 Brisbane M 21 This study
CF07 Melbourne M 5 54
CF13 Auckland M 5 54
CF21 Sydney M 2 54
CF23 Sydney F 2 54
Non-cystic ﬁbrosis strains
PAO1 Melbourne; wound isolate 55
PW8616 PAO1 with transposon insertion phoAwp06q2E07
in ampD gene
56
PW4501 PAO1 with transposon insertion lacZbp01q1C12
in mexZ gene
56
ATCC 25873 USA; blood culture 57
Pa4 Belgium; urinary tract infection 58
Pa5 Belgium; intensive care unit 58
Pa6 Belgium; urinary tract infection 58
aMatching sputum samples were available for all CF isolates except CF07-CF23. All CF isolates were from chronically infected patients, except for 002-A2, 003-A1, and
CF07-CF23.
bM, male; F, female.
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antibiotics selected represented three commonly used classes of anti-Pseudomonas
antibiotics used in the treatment of CF, comprising -lactams (aztreonam, ceftazidime,
meropenem, and ticarcillin-clavulanic acid [Timentin]), an aminoglycoside (tobramycin),
and a ﬂuoroquinolone (ciproﬂoxacin). MICs are shown in Table S1. Using the EUCAST
breakpoints (37), 21% of the strains were resistant to aztreonam, 32% were resistant to
ceftazidime, 63% were resistant to meropenem, 25% were resistant to ticarcillin-
clavulanic acid, 40% were resistant to tobramycin, and 25% were resistant to cipro-
ﬂoxacin. Four isolates showed resistance to all six agents, and a further three strains
were sensitive to only one antibiotic.
Correlation analysis was carried out to test the hypothesis that there is a correlation
between levels of resistance to different antibiotics (Table 2). There was a strong
correlation between MICs for the four -lactam antibiotics aztreonam, ceftazidime,
meropenem, and ticarcillin-clavulanic acid (Spearman’s correlation coefﬁcients  0.74
to 0.93, P  0.001 in all cases). There was also a signiﬁcant, though lower, correlation
between MICs for antibiotics from different classes. For example, resistance to mero-
penem correlated with resistance to tobramycin (Spearman’s correlation coefﬁcient 
0.63, P  0.001), as well as with resistance to ciproﬂoxacin (Spearman’s correlation
coefﬁcient  0.60, P  0.001).
The same antibiotics were examined for their ability to induce the expression of
ampC and mexX in P. aeruginosa reference strain PAO1. Meropenem was the strongest
inducer of ampC expression (8.6-fold), and tobramycin was the strongest inducer of
mexX expression (6.5-fold) (Fig. S1A).
Expression of antibiotic resistance genes in laboratory-grown bacteria.We also
measured the in vitro expression of ampC and mexX among P. aeruginosa isolates
cultured from sputum and grown on laboratory agar in both the presence and absence
of two antimicrobial agents. The results are listed in Table S1 and summarized in Fig.
2. In the absence of antibiotics, the expression of ampC varied over 20,000-fold
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FIG 1 Expression of antibiotic resistance genes in P. aeruginosa in sputum. Expression of ampC and mexX was measured
in 31 sputum samples from patients with cystic ﬁbrosis. (A) The individual expression levels of ampC and mexX (circles),
as well as boxplots showing medians, 25th and 75th percentiles, and minimum and maximum values, are shown. (B)
Comparison of expression of ampC and mexX. Expression of ampC and mexX for each sample is shown.
TABLE 2 Correlations between antibiotic MICsa
Antibiotic Aztreonam Ceftazidime Meropenem Ticarcillin-clavulanic acid Ciproﬂoxacin Tobramycin
Aztreonam 1.00
Ceftazidime 0.84 (0.001) 1.00
Meropenem 0.80 (0.001) 0.91 (0.001) 1.00
Ticarcillin-clavulanic acid 0.88 (0.001) 0.82 (0.001) 0.74 (0.001) 1.00
Ciproﬂoxacin 0.35 (0.0646) 0.55 (0.0026) 0.60 (0.0008) 0.36 (0.0806) 1.00
Tobramycin 0.40 (0.0334) 0.44 (0.0202) 0.63 (0.001) 0.25 (0.2309) 0.58 (0.0030) 1.0000
aMICs were measured for 28 isolates of P. aeruginosa from CF patients (Table S1), and Spearman’s correlation coefﬁcients for pairs of antibiotics are shown. P values
for correlations between values are shown in parentheses. Correlation analysis between MICs of meropenem and tobramycin included data for an additional 11
isolates (Table S1).
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between isolates (range, 0.002 to 46.5; median, 1.28; 25th to 75th percentiles, 0.178 to
10.9). There was less variation in the expression of mexX (range, 0.004 to 7.18; median,
0.189; 25th to 75th percentiles, 0.019 to 1.09), but nonetheless, there was a 2,000-fold
difference in the expression of mexX between the lowest- and highest-expressing
strains. The median expression values for the ﬁve non-CF strains were lower (0.121 for
ampC and 0.011 for mexX) than for the CF strains. Mutations in ampD or mexZ, which
are known regulators of ampC and mexX, respectively (14, 38), resulted in increased
ampC and mexX gene expression in the reference strain PAO1, as expected (Fig. S1B).
There was a correlation between the expression of ampC and mexX for the isolates of
P. aeruginosa from CF patients (Spearman’s correlation coefﬁcient  0.51, P  0.002)
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FIG 2 Expression of antibiotic resistance genes in laboratory-grown bacteria. Expression of ampC and
mexX was determined for 36 isolates of P. aeruginosa from different CF patients cultured in the absence
of antibiotic and for 14 isolates cultured in the presence of sub-MICs of antibiotic. The individual
expression of ampC and mexX (circles), as well as boxplots showing medians, 25th and 75th percentiles,
and minimum and maximum values, are shown. (A) ampC. Median expression of 0.82 (absence of
meropenem) and 4.06 (presence of meropenem). (B) mexX. Median expression of 0.79 (absence of
tobramycin) and 1.01 (presence of tobramycin). (C) Comparison of expression of ampC and mexX in the
absence of antibiotics.
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(Fig. 2C). This is consistent with the strong correlation between resistance to tobramy-
cin and to meropenem (Table 2).
-Lactam antibiotics increase the expression of ampC, and aminoglycoside sub-
strates increase expression of themexXY genes (21). To determine whether this was also
the case for isolates in our study, gene expression was also measured for a subset of 14
isolates from CF patients grown with sub-MICs of meropenem or tobramycin (Fig. 2A
and B). The presence of meropenem increased ampC expression by, on average, 5-fold
across the 14 isolates (Wilcoxon signed-rank test, P  0.001). There was also a strong
intrastrain correlation between gene expression with and without meropenem (Spear-
man’s correlation coefﬁcient  0.78, P  0.001) (Fig. S2A). Likewise, the presence of
tobramycin increased the expression of mexX by, on average, 1.3-fold (P  0.048). The
intrastrain correlation between gene expression with and without added tobramycin
was very strong (Spearman’s correlation coefﬁcient  0.90, P  0.001) (Fig. S2B).
The expression of ampC and mexX was tested for correlation with the MIC of each
strain for meropenem and tobramycin, respectively. The expression of ampC was
correlated with the MIC for meropenem (Spearman’s correlation coefﬁcient 0.49, P
0.003 for bacteria grown in the absence of meropenem) (Fig. S3A), with the correlation
being stronger for bacteria grown in the presence of meropenem (Spearman’s corre-
lation coefﬁcient  0.61, P  0.020) (Fig. S3B). These ﬁndings are consistent with those
of previous studies indicating that the expression of ampC is correlated with -lactam
resistance (22, 30, 39–41), although meropenem is usually not a good substrate for
AmpC -lactamase (42). It remains to be determined whether ampC gene expression in
our samples correlates more strongly with resistance to antibiotics that are better
substrates for the enzyme. The expression of mexX did not correlate with the MIC for
tobramycin when the bacteria were grown in the absence of antibiotic (Spearman’s
correlation coefﬁcient 0.19, P 0.287) (Fig. S3C) but had a non-statistically signiﬁcant
tendency when the bacteria were grown in the presence of tobramycin (Spearman’s
correlation coefﬁcient  0.51, P  0.065) (Fig. S3D). A number of studies have
demonstrated that the MexXYOprM efﬂux pump contributes to aminoglycoside resis-
tance (reviewed in reference 38); for example, the tobramycin MIC of mutants of P.
aeruginosa strain PAO1 lackingmexXY is 4-fold (43) or at least 8-fold (44) lower than that
of isogenic mexXY-containing bacteria. However, resistance to tobramycin is multifac-
torial (14, 21), and a recent study indicates that some isolates of P. aeruginosa with high
expression of the mexXYoprM efﬂux pump are nonetheless susceptible to tobramycin
(45). It is likely that the effects of differences in the expression of mexX on tobramycin
resistance are masked by other resistance mechanisms for the isolates of P. aeruginosa
examined in this study.
Relationship between resistance gene expression in sputum and laboratory-
grown bacteria. The expression of ampC was lower in bacteria in the sputum samples
than for the corresponding bacteria grown on laboratory agar without antibiotic or in
the presence of meropenem, but the difference was not statistically signiﬁcant (Wil-
coxon signed-rank test, P  0.052 and 0.062, respectively). However, there was some
correlation between the expression of ampC in sputum samples and the expression of
ampC by the corresponding P. aeruginosa isolates grown without antibiotics (Spear-
man’s correlation coefﬁcient  0.37, P  0.046) (Fig. 3A). These ﬁndings indicate a
degree of relationship between gene expression in sputum and expression in the
corresponding bacteria grown in culture, although the different physiology of P.
aeruginosa during infection may involve lower expression of ampC. The expression of
ampC in sputum samples was not signiﬁcantly correlated with the expression of ampC
in bacteria grown on meropenem-containing agar (Rho  0.464, P  0.151).
Conversely, the expression of mexX was higher in sputum samples than when the
corresponding bacteria were grown in the laboratory without antibiotics (Wilcoxon
signed-rank test, P  0.002). It was also higher than for bacteria grown on agar
containing tobramycin, although the difference was not statistically signiﬁcant (P 
0.328). The expression of mexX in bacteria in sputum did not correlate with expression
Martin et al. Antimicrobial Agents and Chemotherapy
November 2018 Volume 62 Issue 11 e01789-18 aac.asm.org 6
 o
n
 N
ovem
ber 7, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
of mexX by the corresponding P. aeruginosa grown on agar (Fig. 3C and D, Spearman’s
correlation coefﬁcient, P  0.811 and 0.433).
Gene expression of bacteria in sputum was also compared with the MICs of the
corresponding P. aeruginosa isolates. There was no signiﬁcant correlation between the
expression of ampC in sputum and the MIC of isolated bacteria for meropenem
(Spearman’s correlation coefﬁcient, P  0.252), nor between the expression of mexX in
sputum and the MICs of isolated bacteria for tobramycin (Spearman’s correlation
coefﬁcient, P  0.116).
DISCUSSION
In this research, we investigated the expression of two key P. aeruginosa antibiotic
resistance genes, ampC and mexX, during infection in CF. Samples from patients at four
different hospitals (three different cities) and with a wide range of ages were analyzed
to represent a diversity of CF patients. Both ampC and mexX were expressed during
infection, but there was a remarkably wide range of expression of both genes. The wide
range of gene expression extended to bacteria isolated from sputum and grown in
laboratory culture. In pairwise comparisons, the expression of ampC in bacteria in
sputum was not signiﬁcantly different from that in laboratory-grown bacteria; the
expression ofmexX was slightly higher in sputum than for bacteria grown on laboratory
agar.
There was high variation in the expression of both ampC (over 20,000-fold) and
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FIG 3 Comparison of antibiotic resistance gene expression in bacteria in sputum and in cultured bacteria. (A) Expression of ampC in
cultured bacteria grown in the absence of meropenem was correlated with expression in the corresponding sputum sample (n  31,
Spearman’s correlation coefﬁcient  0.367, P  0.046). (B) Expression of ampC in cultured bacteria grown in the presence of
meropenem was not correlated with expression in the corresponding sputum sample (n  11, Spearman’s correlation coefﬁcient 
0.464, P  0.151). (C) Expression of mexX in cultured bacteria grown in the absence of tobramycin was not correlated with expression
in the corresponding sputum sample (n  31, Spearman’s correlation coefﬁcient  0.007, P  0.973). (D) Expression of mexX in
cultured bacteria grown in the presence of tobramycin was not correlated with expression in the corresponding sputum sample (n 
11, Spearman’s correlation coefﬁcient  0.264, P  0.433).
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mexX (2,000-fold) among isolates of P. aeruginosa grown on laboratory agar. Other
researchers have also reported extensive variation in the expression of these genes
among isolates of P. aeruginosa from a number of clinical settings (25, 27, 30, 39–41),
reﬂecting the frequent occurrence of mutations that result in upregulation of ampC and
mexX in clinical isolates of P. aeruginosa (22–31).
Meropenem increased the expression of ampC, and tobramycin increased expres-
sion of mexX in the isolates in our study. These ﬁndings are consistent with antibiotic-
inducible expression of ampC and mexX in the type strain P. aeruginosa PAO1 (14, 38),
although to the best of our knowledge, the effects of sub-MIC amounts of antibiotics
on the expression of ampC and mexX in clinical isolates of P. aeruginosa have not been
examined previously. There was also a correlation between the expression of ampC and
that ofmexX for the laboratory-grown bacteria. ampC andmexX are not known to share
a regulatory mechanism. It is plausible that prolonged exposure to antibiotics during
chronic CF infection selects for independently arising mutations that cause higher
expression of the ampC and mexX genes.
This possibility is consistent with the strong correlation between resistances to
different antibiotics (-lactams, an aminoglycoside, and a ﬂuoroquinolone) for the
isolates tested, both within and between antibiotic classes (Table 2), something that
has been observed previously (46, 47). Correlation, especially between different classes of
antibiotics, could reﬂect patient treatment with prolonged administration of multiple
antibiotics selecting for mutants with increased resistance to different antibiotic classes due
to multiple independent resistance mechanisms. However, a correlation between resis-
tance to different antibiotics may also result from shared resistance mechanisms, such as
reduced access of multiple -lactams to P. aeruginosa (14, 30), or enhanced activity of efﬂux
pumps that export multiple antibiotics, including different antibiotic classes (14).
The expression of antibiotic resistance genes in sputum samples varied over 4,000-
fold for ampC and approximately 100-fold for mexX. The occurrence of sputum samples
with low levels of expression of ampC and/or mexX indicates that at least under some
circumstances, even low levels of transcription are sufﬁcient to allow survival in CF. The
wide variation in gene expression in P. aeruginosa in laboratory culture indicates that
strain-to-strain variation is at least part of the cause for the range of gene expression
in sputum samples. The expression of ampC was similar in bacteria in sputum to that
in bacteria grown in laboratory medium, and there was a modest correlation between
ampC expression levels in the two environments. Conversely, the expression of mexX
was higher in bacteria in sputum, and expression in laboratory culture did not show
evidence of correlation with expression in sputum. These differences most likely reﬂect
at least in part the difference in physiological states of P. aeruginosa bacteria in the two
different environments. For example, gene expression may be affected by different
growth rates of bacteria in the CF lung and in laboratory culture, by growth in complex
bioﬁlms during infection, by the presence of other bacteria, and by oxidative stress due
to the action of the immune system. Gene expression in sputum could also be affected
by changes in the lung environment during infection, such as the transition between
stable infection and exacerbation, and, as antibiotics inﬂuence gene expression, differ-
ences in the antibiotic treatment received by each patient prior to sample collection.
Furthermore, data from each sputum sample represent the average of the infecting P.
aeruginosa population, which can have considerable genetic and phenotypic hetero-
geneity (11). The individual isolates tested in laboratory culture may therefore not be
representative of the infecting population. Further research analyzing multiple samples
and isolates from individual patients and determining whether there is a correlation
between patient treatment or clinical status and resistance gene expression will be
required to distinguish these possibilities.
Overall, our ﬁndings demonstrate a remarkably wide range of P. aeruginosa antibi-
otic resistance gene expression during infection in CF patients and between isolates of
the bacteria. The reasons for this high patient-to-patient variability, which may inﬂu-
ence the effectiveness of treatment, remain to be determined. The presence of antibi-
otics increased the expression of resistance genes of clinical isolates of P. aeruginosa in
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vitro and will be important to determine the extent to which antibiotic treatment
affects resistance gene expression in infections. The differences in expression of ampC
and mexX during infection and in laboratory-grown bacteria emphasize the different
physiology of P. aeruginosa in the two environments and the importance of investi-
gating the physiology of P. aeruginosa within the human host.
MATERIALS AND METHODS
Subjects and sampling. Sputum samples were collected under the approval of the Southern
Tasmanian Health and Medical Research Ethics Committee (H9813), the Queensland Children’s Health
Services (RCH) Human Research Ethics Committee (HREC/11/QRCH/163), the Metro North Hospital and
Health Service Human Research Ethics Committee of The Prince Charles Hospital (HREC/08/QPCH/87),
and the New Zealand Health and Disability Ethics Committees (NTY/10/12/106). Written informed
consent was obtained for all study participants. Individuals with CF were recruited from outpatient clinics
and inpatients being treated for pulmonary exacerbations. P. aeruginosa was isolated from samples of
sputum using cetrimide agar (Oxoid) or by growth on nonselective agar followed by conﬁrmatory PCR
testing, as described previously (48). For isolation of RNA, sputum was expectorated directly into
RNAlater (Qiagen) and stored at 4°C. A total of 36 sputum samples for RNA analysis were collected from
CF patients in Dunedin (New Zealand), Brisbane (Queensland, Australia), and Hobart (Tasmania, Australia)
(Table 1). Patients were 83% adults, with an age range of 11 to 58 years and median age of 24 years
(interquartile range, 21 to 28 years). All of these patients except for three (those with isolates 002-A2,
003-A1, and 030-1) were chronically infected with P. aeruginosa. P. aeruginosa was analyzed from a
further four samples from CF patients for which sputum for RNA analysis was unavailable. Five reference
strains of P. aeruginosa from non-CF infections (Table 1) were included for comparison in some analyses.
Expectorated sputum was obtained from 36 patients attending four different CF centers (Dunedin,
Hobart, and two independent hospitals in Brisbane).
Antibiotic sensitivity testing. Antibiotic sensitivity testing was carried out using the protocol of
Weigand et al. (49). Overnight cultures of P. aeruginosa grown in King’s B broth (50) were diluted to
approximately 106 CFU/ml, and 5-l portions were inoculated as spots onto plates of Mueller-Hinton agar
(Becton Dickinson) containing doubling dilutions of antibiotic. After the spots had dried, the plates were
incubated at 37°C for 24 h. The MIC was deﬁned through visual examination as the lowest concentration
of antibiotic that inhibited the growth of the bacteria.
RT-qPCR. RNA was extracted from sputum samples that had been collected into RNAlater, as
described previously (51). RNA was also extracted from bacteria that had been spread onto Mueller-
Hinton agar, supplemented as required with meropenem or tobramycin (one-third of the MIC), and
incubated overnight at 37°C. Bacteria were collected into 1 ml of a 2:1 mixture of RNAprotect (Qiagen)
and King’s B broth. Following centrifugation, the bacterial cell pellet was resuspended in 200 l of
Tris-EDTA (TE) buffer containing lysozyme (1 mg/ml) and incubated for 5 min at room temperature to lyse
the bacteria. RNA was then extracted as described above.
Aliquots of RNA were reverse transcribed to make cDNA, and transcripts were quantiﬁed by RT-qPCR,
as described previously (51, 52). Gene-speciﬁc primers for P. aeruginosa ampC (5=-TCG CCT GAA GGC ACT
GGT-3= and 5=-GGT GGC GGT GAA GGT CTT G-3=), mexX (5=-GGC CCT GGT CGC CCT ATT C-3= and 5=-TCC
TCG TAC AGG CGA CGG-3=), and the reference genes clpX and oprL, established previously (51, 52), were
used. The use of reference genes corrected for differences in bacterial load across different samples.
There was a very strong correlation (Pearson correlation coefﬁcient [R2]  0.91) between the crossing
point (Cp) values obtained with clpX and oprL with the sputum samples used in this study. Primer
ampliﬁcation efﬁciencies were determined using serial dilutions of genomic DNA templates from the
reference strain PAO1 and the clinical isolates DUN002C, DUN005A, 002-A2, and 403-110; these were
between 1.8 and 2.0 for all primer pairs with all templates. Quantitative PCR was carried out using SYBR
green I master mix in conjunction with the LightCycler 480 platform (Roche). All reactions were carried
out in duplicate. The presence of correct products was conﬁrmed by melt curve analysis and by agarose
gel electrophoresis, and the ampliﬁcation efﬁciencies of each reaction were conﬁrmed using LinRegPCR
(53). The expression of antibiotic resistance genes was calculated relative to the geometric mean of clpX
and oprL using the LightCycler software (51).
Statistical analyses. Pairs of outcomes were examined for evidence of monotonic associations using
Spearman’s correlation coefﬁcients (i.e., for values of one outcome showing a positive or negative, but not
necessarily linear, association against the other outcome). Levels of expression were compared between pairs
of outcomes within study participants using Wilcoxon matched-pairs signed-rank tests to determine if
within-participant differences tended to be positive or negative. For these analyses, only participants with
both outcomes measured were able to be included. Analyses were performed using Stata 15.1, and a
two-sided P value of 0.05 was considered statistically signiﬁcant in all cases. Some outcomes were
unavailable for some participants, and all available data were used for each particular analysis.
SUPPLEMENTAL MATERIAL
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